Results 231 to 240 of about 54,087 (251)
Some of the next articles are maybe not open access.
A Direct Antifibrinolytic Agent in Major Orthopedic Surgery
Orthopedics, 2004abstract Aprotinin is a potent pharmacological agent that reduces bleeding. In current surgical practices, the rate of blood transfusions has decreased with the use of aprotinin. Recently, studies using aprotinin have been conducted in orthopedic surgery.
openaire +3 more sources
Trinitrophenyl-Derivative of Urinary Trypsin Inhibitor: A Strong Antifibrinolytic Agent
Acta Haematologica, 1987A trinitrophenyl derivative of urinary trypsin inhibitor (TNP-UTI) was found to demonstrate approximately 50 times stronger antiplasmin fibrinolysis than the intact UTI. Almost no change in antitrypsin or antichymotrypsin activity occurred as a result of the UTI modification.
Masugi Maruyama +6 more
openaire +3 more sources
Structure, Pharmacology, and Clinical Use of Antifibrinolytic Agents
2001Antifibrinolytic therapy constitutes an effective means to control or reduce bleeding and to limit or avoid blood transfusion in current medical practice. During the past 30 years it has been used as an established antidote in patients treated by thrombolytic agents and experiencing bleeding complications.
C. M. Samama +4 more
openaire +2 more sources
A comparison of antifibrinolytic agents used in hemostatic fibrin sealants
Journal of the American College of Surgeons, 2003Fibrin sealants used as hemostatic and adhesive surgical adjuncts invariably combine fibrinogen and thrombin. The use of plasma-derived products to facilitate hemostasis was first described in 1909. Because the approach relied on in vivo concentrations of fibrinogen and thrombin the quality of the resulting fibrin clot was poor.
openaire +3 more sources
Antifibrinolytic Agents in Plastic Surgery: Current Practices and Future Directions
Plastic & Reconstructive Surgery, 2018Background: Prevention of blood loss is a chief consideration in plastic and reconstructive surgery. The antifibrinolytic drugs tranexamic acid and ε-aminocaproic acid have emerged as promising agents to reduce both perioperative blood loss and transfusion requirements.
Peter J. Taub, Amy Yao, Stav Brown
openaire +2 more sources
The plasmin inhibition by synthetic antifibrinolytic agents in relation to the type of substrate
Biochimica et Biophysica Acta (BBA) - Enzymology, 1968The inhibitory effect of synthetic antifibrinolytic agents: e-aminocaproic acid, p-aminomethyl benzoic acid and the active isomer of 1,4-aminomethyl cyclohexane carboxylic acid on plasmin (EC 3.4.4.14), acting on various substrates, was studied. All the inhibitors had a very weak effect, if any at all, on casein and fibrinogen proteolysis by plasmin ...
Hanna Łukasiewicz +3 more
openaire +3 more sources
Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children
2008Scoliosis surgery is often associated with substantial blood loss and potential detrimental effects in children. Antifibrinolytic agents are often used to reduce perioperative blood loss. Clinical trials have evaluated their effect in children undergoing surgical correction of scoliosis but no systematic review has been published.
Aikaterini, Tzortzopoulou +3 more
openaire +2 more sources
Antifibrinolytic Agents in Traumatic Hemorrhage
Annals of Epidemiology, 2006openaire +3 more sources
Antifibrinolytic Agents in Cardiac and Noncardiac Surgery: A Comprehensive Overview and Update
Journal of Cardiothoracic and Vascular Anesthesia, 2017Kirill M. Gelfenbeyn +8 more
openaire +2 more sources